Nighttime melatonin secretion and sleep architecture: different associations in perimenopausal and postmenopausal women by Toffol, Elena et al.
lable at ScienceDirect
Sleep Medicine 81 (2021) 52e61Contents lists avaiSleep Medicine
journal homepage: www.elsevier .com/locate/s leepOriginal ArticleNighttime melatonin secretion and sleep architecture: different
associations in perimenopausal and postmenopausal women*
Elena Toffol a, *, Nea Kalleinen b, c, Sari-Leena Himanen d, e, Timo Partonen f,
Jari Haukka a, d, P€aivi Polo-Kantola c, g
a Department of Public Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland
b Heart Center, Turku University Hospital and University of Turku, Turku, Finland
c Sleep Research Center, Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland
d Faculty of Medicine and Health Technology, Tampere University, Finland
e Department of Clinical Neurophysiology, Tampere University Hospital, Tampere, Finland
f Mental Health Unit, Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
g Department of Obstetrics and Gynecology, Turku University Hospital and Turku University, Turku, Finlanda r t i c l e i n f o
Article history:
Received 31 August 2020
Received in revised form
1 February 2021
Accepted 2 February 2021







Melatonin* The study was registered as a European Researc
menopausal and postmenopausal ageing women: p
nisms, animal models, social aspects, treatment an
europa.eu/project/id/QLK6-CT-2000-00499 (QLK6-CT-
* Corresponding author. Department of Public He
Helsinki, Po Box 20 (Tukholmankatu 8 B), 00014, Hel
E-mail address: elena.toffol@helsinki.fi (E. Toffol).
https://doi.org/10.1016/j.sleep.2021.02.011
1389-9457/© 2021 The Authors. Published by Elseviea b s t r a c t
Background: Sleep quality typically decreases after menopause, but the underlying mechanisms are
poorly understood. Concentrations of melatonin are lower and its secretion profiles different before and
after menopause. However, whether and how melatonin and sleep architecture are associated in women
of different reproductive states have not been examined to date.
Methods: Overnight serum melatonin samples were taken from 17 perimenopausal and 18 post-
menopausal healthy women. Sleep quality was measured with all-night polysomnography recordings.
Results: Melatonin concentrations tended to be the lowest during NREM sleep, and were associated with
higher odds of transitions from wake to NREM sleep. The curves of predicted overnight melatonin values
from linear mixed models varied according to sleep phases (NREM, REM, Wake) in perimenopausal, but
not in postmenopausal women. In perimenopause higher melatonin area under curve (AUC) correlated
with higher slow-wave activity (p ¼ 0.043), and higher minimum concentrations with shorter slow-wave
sleep (SWS) latency (p ¼ 0.029). In postmenopause higher mean and maximum melatonin concentra-
tions and AUC correlated with lower SWS percentage (p ¼ 0.044, p ¼ 0.029, p ¼ 0.032), and higher mean
(p ¼ 0.032), maximum (p ¼ 0.032) and minimum (p ¼ 0.037) concentrations with more awakenings from
REM sleep. In the age- and BMI- adjusted regression models, the association between higher maximum
(p ¼ 0.046) melatonin concentration and lower SWS percentage remained.
Conclusions: The relationship between melatonin and sleep architecture differed in perimenopausal and
postmenopausal women. After menopause, high melatonin concentrations were associated with worse
sleep. Whether these different patterns are related to aging of the reproductive system, and to decrease
in menopausal sleep quality, remains to be elucidated.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The decrease in sleep quality during the menopausal transition,
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r B.V. This is an open access articleestablished [1e3]. This evidence is further supported by the
beneficial effects of replacing the lack of estrogens with meno-
pausal hormone therapy (MHT), which is shown to abolish or at
least alleviate sleep disturbances [4e6]. One of the most important
underlying causes are the climacteric vasomotor symptoms, such as
nocturnal hot flushes and sweating [5,7], symptoms which are
significantly reduced with MHT. However, although a proportion of
women with menopausal sleep disturbances do not report vaso-
motor symptoms, they similarly seem to benefit from MHT [4].
To date, sleep studies using polysomnography (PSG) and
conventionally evaluating sleep time, sleep efficiency, sleep stage
distributions and number of awakenings, have failed to explain theunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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[5,8]. Most of these studies have found worse self-reported sleep
quality, but none or only minimal alterations in sleep architecture
[3,5,9e14]. Rather, some authors have found a better objectively
measured sleep quality and longer sleep duration in post-
menopausal than in premenopausal women [10,15,16]. Because
sleep is regulated via complex neurochemical systems including
circadian rhythm regulators and hormones, it is not surprising that
the underlying factors causing subjective and objective sleep dis-
turbances in postmenopausal women are still not clear. One of the
likely regulators of sleep is melatonin. Because melatonin produc-
tion and secretion profiles are mainly regulated by the circadian
cycle, andmodified by the lightedark cycle, the plasma levels are at
their lowest during the day, start to rise in the evening and peak at
night. Specifically, a morning oscillator regulates melatonin offset
time, and an evening oscillator its onset time, with sleep onset
normally occurring approximately two hours aftermelatonin onset.
Thus, melatonin is one of the best indicators of circadian rhythms in
humans, including the sleep-wake cycle, and specifically regulates
the timing of sleep.
Alterations in melatonin levels and secretion profile have been
suggested as a possible underlying mechanism in the sleep
disruption typical of many conditions, such as the delayed and
advanced sleep phase syndromes, sleep disturbances related to jet
lag and shift work, and, most likely, the sleep alterations typically
found in the elderly [17]. Individuals with low endogenous mela-
tonin secretion had longer sleep onset latency and REM latency, as
well as lower sleep efficiency and REM percentage than normal
secretors [18].
In 1982, Birkeland analyzed the secretion profile of nighttime
melatonin in seven healthymen in relation to their sleep stages and
found that melatonin levels were the highest during wake and the
lowest during REM sleep [19]. Results of later studies are, however,
inconsistent, showing either no associations, or highest and lowest
melatonin levels in NREM and REM sleep, respectively [20e22].
Importantly, all these previous studies were conducted in men of
different age groups. To the best of our knowledge, to date (PubMed
search on 29 June 2020) no study has specifically examined the
associations between melatonin secretion and sleep architecture,
and the associations between melatonin, sleep stages and sleep
stage transitions in women, and specifically in women of different
reproductive states.
In this study we aimed to examine whether melatonin con-
centrations and secretion profile are related to sleep architecture,
and whether melatonin concentrations are associated to the di-
rection of sleep stage transitions. Because we have previously
shown that melatonin concentrations were lower and the secretion
profiles different in postmenopause than in perimenopause [23],
we hypothesized that the associations, if any, are different between
perimenopausal and postmenopausal women. We also hypothe-
sized that these changes in melatonin secretion after the meno-
pause are associated with worse sleep structure.
2. Methods
2.1. Subjects
This work was part of a larger study conducted at the Turku
University Hospital and at the University of Turku (Finland), aimed
to evaluate the effects of menopause on sleep and cognition.
Altogether 17 perimenopausal (aged 43e51 years) and 18 post-
menopausal (aged 58e71 years) women were recruited through
advertisements in the local newspapers in the area of Turku. Peri-
menopausal status was defined by the serum follicle stimulating
hormone (FSH) level (<23 IU/ml) and an ongoing regular or53irregular menstrual cycle. Postmenopause was defined by age (58
years) and at least 12 months of amenorrhea.
Women experiencing a mental, cardiovascular (with the
exception of drug-treated balanced hypertension), endocrine (with
the exception of drug-treated balanced hyperlipidemia), pulmo-
nary, neurological or specific sleep disorder (eg sleep apnea, nar-
colepsy or restless leg syndrome), or malignancies were excluded
from the study. Additional exclusion criteria included alcohol
abuse, smoking, excessive caffeine intake (>5 cups per day), use of
other substances known to affect the central nervous system and
other conditions possibly affecting sleep (eg fibromyalgia and
anemia). All women had normal levels of blood hemoglobin, leu-
kocytes, thrombocytes and serum thyrotropin. A washout period of
at least 12 months was required for women who had previously
used MHT (one perimenopausal and 13 postmenopausal women).
Six of the perimenopausal and three of the postmenopausal women
reported using Nonsteroidal anti-inflammatory drugs (NSAIDs);
moreover, one perimenopausal and three postmenopausal women
used beta-blockers. More details about the data collection and
study design have already been described elsewhere [11]. After
receiving oral and written information, all women gave written
informed consent. The study was approved by the Ethics Com-
mittees of Turku University Hospital and of University of Turku,
Finland.
All the participants kept a sleep diary during the three weeks
before and one week after the study to verify their sleep-wake
rhythms. All women had regular sleep-wake schedules (from
22:00e23:00 h to 06:00e07:00 h). Oneweek before and during the
study women were not allowed to travel abroad, as well as to use
alcohol and caffeine. Coffee-drinkers were provided with decaf-
feinated beverages. The women spent three consecutive nights in
the sleep laboratory: one adaptation night, the second night as a
baseline night and the third night with repeated blood sampling.
Every evening they arrived to the sleep laboratory at 19:30 h and
the all-night polysomnography (PSG) recording was performed
from 23:00 (lights-off) to 07:00 (lights-on). During the nights only
red light was allowed for illumination if needed. Therefore, during
the study period the women spent their time inside a building, in a
dark room without windows, with strictly controlled nighttime
illumination levels; this protocol limited the possible influence of
different photoperiods in different subjects. The study was per-
formed by similar timetable in all subjects and food was provided
by the sleep laboratory. One perimenopausal woman was not
willing to continue the study after the first night, and thus she was
excluded from the current study.
2.2. Sleep architecture
The all-night PSG recordings consisted of continuous moni-
toring via electroencephalograms (EEG; channels C3/A2, C4/A1, O1/
A2 and O2/A2), electro-oculograms (EOG), a mandibular electro-
myogram (EMG) and an electrocardiogram (ECG, Embla®, Medcare
Flaga hf. Medical devices, Reykjavik, Iceland). Sleep stages were
visually scored in 30-s epochs according to conventional criteria
valid during the data collection (years 2001e2004) [24] by the
same scorer (NK) and controlled by a senior scorer (PPeK). For the
purpose of this study, three groups of sleep variables were
considered as follows.
First, general sleep: sleep latency (period from lights-off to
sleep onset, defined as the appearance of three consecutive
epochs of S1 or the first epoch of any other stage); total sleep
time (sum of time spent in Stage 1 (S1), Stage 2 (S2), SWS, REM
sleep and movement time [MT]); sleep efficiency (the percent-
age of total sleep time out of time in bed); number of arousals
(EEG a-activity for at least three seconds) [25]; total number of
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sleep stage); wake time after sleep onset (WASO) (the percent-
age of total time in bed, from lights-off to lights-on); and
number of sleep stage transitions.
Second, NREM sleep: S1 percentage (the percentage of total
time in bed, from lights-off to lights-on); S1 awakenings (the
number of times entering wake stage from S1 sleep); S2 percentage
(the percentage of total time in bed, from lights-off to lights-on); S2
awakenings (the number of times entering wake stage from S2
sleep); SWS latency (the time from sleep onset to the first 30 s of
the SWS); SWS percentage (the percentage of total time in bed,
from lights-off to lights-on); SWS awakenings (the number of times
entering wake stage from SWS); and total slow wave activity in
NREM-sleep (SWA, 0.75e4 Hz) [11].
Third, REM sleep: REM latency (the time from sleep onset to the
first 30 s of the REM stage); REM percentage (the percentage of
total time in bed, from lights-off to lights-on); and REM awakenings
(the number of times entering wake stage from REM sleep).
2.3. Blood samples
On the evening before the third night an indwelling catheter
was inserted into a forearm vein to permit a 24-h blood sampling at
20-min intervals, starting from 21:00 h. At night (from 21:00 h to
07:00 h) the catheter was connected to a plastic tube extending into
an adjacent room, allowing repeated blood sampling without dis-
turbing the woman's sleep. The catheter was kept patent with a
slow heparinized saline infusion. Melatonin measurements were
available for 20-min interval samples between 21:00 andmidnight,
and from 06:00 to 09:00; measurements on one-hour interval
samples were available between midnight and 06:00. All peri-
menopausal women were examined in the beginning of their
menstrual cycle (in the follicular phase). The blood samples were
collected all throughout the year; in detail, 12 of the 16 perimen-
opausal women, and 10 of the 18 postmenopausal women were
assessed during winter time (October to March).
The blood samples were drawn into EDTA tubes and placed in
the refrigerator for 20 min. Thereafter, they were centrifuged to
separate serum, which was frozen at 70 C until assayed. For
melatonin analyses the serum samples were first extracted with
chloroform and then assayed by radioimmunoassay with an
iodinated melatonin tracer and a melatonin-specific antiserum
[26]. The lowest detectable concentration by the method was
1.3 pg/ml (5.7 pmol/l), and the intra-assay and inter-assay co-
efficients of variation were from 6.7 to 9.5% and from 9.8 to 12.5%,
respectively.
The following five groups of melatonin indicators, two of con-
centration (#1-#2) and three of secretion (#3-#5), were derived: 1)
the mean and median nighttime serum melatonin concentrations
between lights-off (at 23:00 h) and lights-on (at 07:00 h); 2) the
maximum and minimum levels of nighttime serum melatonin
concentrations (between lights-off and lights-on); 3) the nighttime
melatonin exposure level: after the interpolation of melatonin
exposure level curve, the area under melatonin exposure curve
(AUC, from lights-off to lights-on) was calculated for each indi-
vidual; 4) the duration of nighttime melatonin secretion: the total
amount of time (in hours) when serum melatonin levels (circu-
lating melatonin) were 10 pg/ml, where 10 pg/ml is the usual
threshold for melatonin onset; 5) the time from lights-off to
melatonin peak time (in hours).
2.4. Questionnaire variables
The level of self-reported sleep disturbances during the
previous three months was evaluated with the Basic Nordic54Sleep Questionnaire (BNSQ) [27], and sum-scores for insomnia
(difficulty falling asleep, nocturnal awakenings þ their nocturnal
frequency, early morning awakenings and sleep quality in the
past three months, with the range of 5e25) were calculated
accordingly, with a lower score indicating better sleep. Climac-
teric vasomotor symptoms during the previous six months were
assessed with two questions inquiring into nocturnal hot flashes
and sweating. The frequency of both symptoms (sum score,
range 2e8) was determined on the basis of the following four-
point scale: one (“seldom or never”), two (“approximately once
a month”), three (“approximately once a week”), four (“almost
every day”). The presence of depressive symptoms during the
previous four weeks was assessed via the 21-item Beck
Depression Inventory (BDI) [28], a sum score, with the range of
0e63.
2.5. Statistical analysis
The distribution of variables was tested via visual inspection of
histograms and ShapiroeWilk test.
A model with three sleep phases (wake, NREM, REM) was
identified via multi-state models as the best fitting model for
analyzing the PSG data. For the following analyses, only melatonin
measurements between the first sleep onset after lights-off until
lights-on were used. Median melatonin levels in each sleep phase
were compared via Wilcoxon-rank-sum test in the whole sample,
and separately in perimenopausal and postmenopausal women. By
using linear mixed model regression analyses, we tested associa-
tions between repeated measurements of melatonin levels during
sleep (between the first sleep onset after lights-off, until lights-on)
and sleep phases (wake, NREM, REM). In these analyses, repeated
melatonin measurements were used as the outcome variable, the
individual as a random effect, and sleep phase and time of mela-
tonin measurement as fixed explanatory variables. Interaction be-
tween time and sleep phases was tested using log-likelihood test.
According to the best fitting model based on Akaike Information
Criterion, measurement time was entered both as linear and
quadratic terms, reflecting the melatonin secretion curve. Analyses
were carried out separately in perimenopasual and post-
menopausal women. In addition to the unadjusted model (Model
1), three multivariable models were performed to control for the
effect of age and body mass index (BMI, kg/m2) (Model 2), age, BMI
and climacteric symptom score (Model 3), and age, BMI and BDI
score (Model 4). Multi-state models with sleep phases (wake,
NREM, REM) andmelatonin concentrations (at eachmeasurement),
reproductive status (postmenopausal vs. perimenopausal), and
time-dependent intensity for transitions as covariates were addi-
tionally performed to test the predictive values of covariates on
sleep phases [29].
Pearson and Spearman analyses, as appropriate, were per-
formed to examine the correlations between nighttime serum
melatonin concentrations (mean, median, minimum and
maximum), melatonin exposure level (AUC), duration of nighttime
melatonin secretion and the time from lights-off to melatonin peak,
vs. sleep variables, separately in perimenopausal and post-
menopausal women. Univariable (Model 1) and progressively
adjusted multivariable generalized linear models (Model 2:
controlled for age and BMI; Model 3: controlled for age, BMI and
climacteric vasomotor symptom score; Model 4: controlled for age,
BMI and BDI score) were performed, separately in perimenopausal
and postmenopausal women, to test the associations between
melatonin and sleep variables.
The statistical analyses were performed using the R program
(version 3.5.2) [30]. For all the analyses, the two-tailed p-values of
<0.05 were considered statistically significant.
Fig. 1. An individual curve of sleep stages and melatonin levels (blue curves). Gray
curves are melatonin level curves for each individual.
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Postmenopausal women had higher BNSQ insomnia score
(mean ¼ 16.0, SD ¼ 4.0) and BDI score (mean ¼ 6.3, SD ¼ 4.9)
compared to perimenopausal women (mean ¼ 13.4, SD ¼ 3.4,
p ¼ 0.046; and mean ¼ 3.6, SD ¼ 2.9, p ¼ 0.032, respectively),
showing a higher level of self-reported sleep disturbances and of
depressive symptoms. Postmenopausal women had also higher
BMI (mean ¼ 27.6, SD ¼ 5.0) than the perimenopausal ones
(mean¼ 24.3, SD¼ 2.4, p¼ 0.015). However, the two groups did not
differ with respect to their levels of climacteric symptoms (peri-
menopause: mean ¼ 2.6, SD ¼ 0.8; postmenopause: mean ¼ 4.2,
SD ¼ 2.5, p ¼ 0.120). Postmenopausal women had lower levels of
mean melatonin (from lights off to light on; mean ¼ 17.0, SD ¼ 6.8)
compared to those in perimenopause (mean ¼ 24.0, SD ¼ 10.0,
p ¼ 0.026).
3.1. Melatonin and sleep phases
Fig. 1 illustrates one individual example curve of overnight
melatonin concentrations in relation to sleep stages. Median
melatonin concentrations and interquartile ranges during each
sleep phase (wake, NREM and REM) are reported in Table 1. Both in
perimenopausal and in postmenopausal women, melatonin con-
centrations were the lowest during the NREM sleep, although the
difference was not significant.Table 1
Median melatonin levels (pg/mL) and interquartile ranges (IQRs) across sleep phases.
wake NREM
na median (IQR) na m
All women 120 19.15 (12.10, 28.80) 231 1
Perimenopause 50 25.30 (15.10, 35.70) 115 2
Postmenopause 70 16.50 (11.70, 23.50) 116 1
NREM sleep phase includes stage 1, stage 2 and slow wave sleep.
a n refers to the total number of available melatonin observations for each sleep phas
b p-value from Wilcoxon test.
55Results of linear mixed models showed that in perimenopausal
women overnight melatonin concentrations tended to be lower
during the NREM sleep compared to the wake phase (p ¼ 0.074).
The interaction between time and NREM sleep in predicting
melatonin concentrations showed that the rate of linear change in
melatonin concentrations during the night was faster, and the
quadratic change slower during NREM sleep than during the wake
phase (b ¼ 0.45; 95% CI ¼ 0.07 to 0.84; p ¼ 0.019; b ¼ 0.05; 95%
CI ¼ 0.09 to 0.003; p ¼ 0.038). The results did not change after
controlling for covariates (age, BMI, climacteric vasomotor
symptom score and BDI score). No associations between mela-
tonin concentrations and sleep phases were found in postmeno-
pause (Table 2). Accordingly, the curves of predicted values of
overnight melatonin concentrations varied according to sleep
phases in perimenopausal, but not in postmenopausal women
(Fig. 2). Predicted values for each woman are illustrated in Figs. S1
and S2.
The total number of sleep stage transitions is reported in Table 3.
In multi-state models, higher point concentrations of melatonin
were associatedwith higher odds of transitions fromwake to NREM
sleep. Postmenopausal state was associated with higher odds of
transitions fromwake to NREM, NREM to wake, and REM to NREM
(Table 3).
3.2. Melatonin and sleep variables
In perimenopause higher minimum melatonin concentra-
tions related to shorter SWS latency (r ¼ 0.55, p ¼ 0.029),
and higher melatonin AUC related to higher amount of SWA
(r ¼ 0.51, p ¼ 0.043). In postmenopausal women higher
melatonin mean and maximum concentrations and AUC
correlated with lower SWS percentage (r ¼ 0.48, p ¼ 0.044;
r ¼ 0.52, p ¼ 0.029; and r ¼ 0.51, p ¼ 0.032, respectively).
Additionally, higher mean, median, minimum and maximum
melatonin concentrations correlated with more REM awaken-
ings (r ¼ 0.51, p ¼ 0.032; r ¼ 0.52, p ¼ 0.026; r ¼ 0.50,
p ¼ 0.037; and r ¼ 0.51, p ¼ 0.032, respectively) (Fig. 3, Fig. 4
and Fig. S3).
In generalized linear models no associations were found be-
tween melatonin peak time, melatonin AUC or duration of
melatonin secretion and sleep variables, neither in perimeno-
pausal nor in postmenopausal women. However, in post-
menopausal women only, higher mean and maximum melatonin
concentrations were (or tended to be) associated with lower SWS
percentage in univariable (b ¼ 0.63, 95% CI ¼ 1.20 to 0.07,
p ¼ 0.044; and b ¼ 1.19, 95% CI ¼ 2.15 to 0.22, p ¼ 0.029) and
age- and BMI- adjusted models (b ¼ 0.62, 95% CI ¼ 1.25 to
0.001, p ¼ 0.071; and b ¼ 1.18, 95% CI ¼ 2.23 to 0.13,
p ¼ 0.046) (Fig. 4). The associations were lost when further
controlling for climacteric vasomotor symptom score (p ¼ 0.134
and p ¼ 0.113, respectively), or BDI score (p ¼ 0.143, and
p ¼ 0.084, respectively).REM p-valueb
edian (IQR) na median (IQR)
8.40 (11.10, 30.25) 47 20.20 (14.00, 39.10) 0.314
1.60 (13.10, 37.55) 21 24.00 (14.30, 40.00) 0.812
3.80 (10.10, 24.80) 26 16.75 (13.87, 31.72) 0.123
e.
Table 2
Linear mixed model analyses of associations between repeated measures of melatonin concentrations and wake (as reference), NREM and REM sleep phases.
Model 1 Model 2 Model 3 Model 4
В 95% CI p-value b 95% CI p-value b 95% CI p-value b 95% CI p-value
Perimenopausal women
NREM sleep 0.63 1.33 to 0.06 0.074 0.65 1.34 to 0.05 0.069 0.64 1.34 to 0.06 0.072 0.61 1.31 to 0.09 0.088
REM sleep 0.64 2.17 to 0.89 0.41 0.70 2.23 to 0.83 0.37 0.69 2.22 to 0.84 0.38 0.62 2.16 to 0.92 0.43
Sampling time 0.40 0.07 to 0.73 0.018 0.40 0.06 to 0.73 0.020 0.40 0.07 to 0.73 0.019 0.41 0.08 to 0.74 0.016
Sampling time2
(quadratic term)
0.04 0.08 to 0.004 0.029 0.04 0.08 to 0.004 0.031 0.04 0.08 to 0.004 0.030 0.04 0.08 to 0.01 0.026
NREM sleep * time
interaction
0.45 0.07 to 0.84 0.019 0.46 0.08 to 0.84 0.018 0.46 0.08 to 0.84 0.018 0.44 0.06 to 0.83 0.023
REM sleep * time
interaction
0.63 0.15 to 1.41 0.11 0.66 0.13 to 1.44 0.10 0.65 0.13 to 1.44 0.10 0.62 0.17 to 1.41 0.12
NREM sleep * time2
interaction
0.05 0.09 to 0.003 0.038 0.05 0.09 to 0.003 0.035 0.05 0.09 to 0.003 0.036 0.04 0.09 to 0.001 0.044
REM sleep * time2
interaction
0.07 0.16 to 0.02 0.12 0.07 0.16 to 0.02 0.11 0.07 0.16 to 0.02 0.11 0.07 0.16 to 0.02 0.12
Postmenopausal women
NREM sleep 0.04 0.47 to 0.38 0.84 0.04 0.46 to 0.39 0.87 0.03 0.46 to 0.40 0.89 0.03 0.45 to 0.39 0.89
REM sleep 0.87 1.98 to 0.25 0.13 0.86 1.97 to 0.26 0.13 0.84 1.95 to 0.27 0.14 0.92 2.03 to 0.20 0.11
Sampling time 0.63 0.44 to 0.82 <0.001 0.63 0.44 to 0.82 <0.001 0.63 0.44 to 0.82 <0.001 0.63 0.44 to 0.82 <0.001
Sampling time2
(quadratic term)
0.07 0.09 to 0.05 <0.001 0.07 0.09 to 0.05 <0.001 0.07 0.09 to 0.05 <0.001 0.07 0.09 to 0.05 <0.001
NREM sleep * time
interaction
0.01 0.22 to 0.24 0.95 0.002 0.23 to 0.23 0.99 0.004 0.23 to 0.24 0.98 0.002 0.23 to 0.23 0.98
REM sleep * time
interaction
0.38 0.16 to 0.91 0.17 0.37 0.16 to 0.90 0.17 0.37 0.16 to 0.90 0.17 0.40 0.14 to 0.93 0.15
NREM sleep * time2
interaction
0.001 0.03 to 0.03 0.91 0.002 0.02 to 0.03 0.87 0.002 0.02 to 0.03 0.89 0.002 0.02 to 0.03 0.88
REM sleep * time2
interaction
0.03 0.09 to 0.02 0.26 0.03 0.09 to 0.02 0.27 0.03 0.09 to 0.03 0.27 0.03 0.09 to 0.02 0.24
NREM sleep stage includes stage 1, stage 2 and slow wave sleep.
Model 1: a mixed linear model with sleep stage as predictor, sampling time (linear and quadratic terms) as fixed effect, and individual as the random effect.
Model 2: is Model 1 adjusted for age and BMI.
Model 3: is Model 1 adjusted for age, BMI and climacteric vasomotor symptom score.
Model 4 is Model 1 adjusted for age, BMI and BDI score.

















Fig. 2. Curve of predicted values of melatonin by sleep phases (wake, NREM, REM) in one perimenopausal (panel A) and postmenopausal (panel B) woman. Predicted values
are from unadjusted linear mixed models.
Table 3
Associations between sleep phase transitions, time-point melatonin concentrations and postmenopausal vs. perimenopausal state.
Sleep phase transition Number of transitions Melatonin (pg/mL) Postmenopausal vs. Perimenopausal
Hazard ratio 95% CI Hazard ratio 95% CI
Wake / NREM 754 1.02 1.01 to 1.02 1.33 1.14 to 1.55
Wake / REM 51 1.02 1.00 to 1.05 1.48 0.73 to 3.01
NREM / Wake 653 1.00 1.00 to 1.00 1.28 1.08 to 1.51
NREM / REM 343 1.00 1.00 to 1.01 1.13 0.90 to 1.42
REM / Wake 142 1.01 0.99 to 1.02 1.01 0.70 to 1.44
REM / NREM 250 1.00 0.99 to 1.00 1.34 1.02 to 1.77
NREM sleep stage includes stage 1, stage 2 and slow wave sleep.
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We found associations between levels of melatonin and the
NREM sleep, as well as different predicted curves of melatonin
levels across sleep phases, only in perimenopausal women. In
addition, in perimenopause indicators of high melatonin levels
were related to better NREM sleep (shorter SWS latency and higher
amount of SWA), whereas in postmenopause markers suggestive of
higher melatonin levels were related to more disrupted NREM and
REM sleep, as indicated by a lower SWS percentage and more57awakenings from REM sleep, respectively. Consistently, post-
menopausal status, but not melatonin concentrations, was a
stronger predictor of sleep phase transitions.
This study is the first to assess the connections of nighttime
melatonin concentrations and secretion with sleep architecture in
women of two different reproductive phases. Even if the difference
did not reach the significance level, median melatonin concentra-
tions were the lowest during the NREM sleep, both in perimeno-
pausal and in postmenopausal women. In addition, in
perimenopausal women the NREM sleep tended to be associated
Fig. 3. Correlations between sleep variables and melatonin secretion profile in perimenopausal (A) and postmenopausal (B) women. Numbers indicate correlation co-
efficients. Significant correlations are marked in red (*p ¼ 0.043 for both). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version
of this article.)
Fig. 4. Correlations and associations between melatonin concentration and secretion parameters, and sleep variables in perimenopausal and postmenopausal women. The
figure displays significant correlations between melatonin and sleep variables. Results that were significant (or tended to be significant) also in unadjusted and age- and BMI-
adjusted regression analyses are marked in orange. Numbers are b coefficients, 95% CIs and p-values from unadjusted models. Regression coefficients (b) indicate one unit change in
melatonin mean and maximum levels (pg/ml) per one unit change in SWS percentage. (For interpretation of the references to color in this figure legend, the reader is referred to the
Web version of this article.)
E. Toffol, N. Kalleinen, S.-L. Himanen et al. Sleep Medicine 81 (2021) 52e61with lower melatonin concentrations compared to the wake phase,
and the rate of change in melatonin concentrations was associated
with the NREM sleep. Taken together, these results suggest that the58NREM sleep may be themost sensitive tomelatonin concentrations
and secretion profile. This hypothesis seems to be confirmed by the
observation that almost all of the connections between melatonin
E. Toffol, N. Kalleinen, S.-L. Himanen et al. Sleep Medicine 81 (2021) 52e61indicators and sleep architecturemeasurements were related to the
NREM sleep (SWS latency, SWS percentage, SWA). Interestingly, the
connections between melatonin and NREM sleep were of opposite
directions in perimenopausal and postmenopausal women. While
in perimenopause higher melatonin concentrations were related to
better NREM sleep (shorter SWS latency and higher amount of
SWA), in postmenopause higher concentrations of melatonin were
related to poorer NREM sleep, as indicated by lower SWS per-
centage. However, it is of note that most of these associations lost
their significance after adjustment for age, BMI and vasomotor
symptom scores or BDI scores, especially in perimenopause. In fact,
factors such as age, BMI, depressive and climacteric symptoms are
known to be connected to melatonin [31e33]. For example, mela-
tonin concentrations decrease with advancing age [31], which in
turn is associated with poorer sleep. Climacteric symptoms, on the
other hand, are one of the causes of disrupted subjective and
objective sleep in menopausal women [5,34]. It has been hypoth-
esized that melatonin could reduce climacteric vasomotor symp-
toms, for example by suppressing the pulse generator responsible
both for gonadotropin secretion and putatively for the generation
of hot flushes; however, evidence supporting this hypothesis is
rather contradictory [31,35].
On the basis of our results, it appears that melatonin concen-
trations and secretion profile are related to sleep phases differently
before and after menopause, with NREM sleep being the most
sensitive. Whether melatonin has a promotor effect on (NREM)
sleep, or if the sleep phases influence the concentrations and profile
of melatonin secretion, is not clear. It could be speculated that
during perimenopause melatonin indeed contributes to maintain
sleep. However, after menopause, when gonadal hormone levels
change and reach a new balance, the melatonin-sleep regulation
system may change. In this context, the lowered concentrations of
melatonin and the shortened duration of secretion typical of the
postmenopausal period [23] may not be able to positively regulate
sleep. It could be similarly hypothesized that the SWS is differently
effective in perimenopause and postmenopause: thus, before
menopause, high melatonin levels are accompanied by lower
amount of more effective SWS; on the contrary, during postmen-
opause, when the melatonin levels are lower, higher levels of less
effective SWS are required to obtain effective sleep. Hence, our
findings of an association between higher melatonin concentra-
tions and poorer sleep (less SWS percentage and more REM
awakenings) in postmenopause may reflect a compensatory
mechanism, ie, the deteriorated sleep may itself induce a
compensatory melatonin rise, possibly through a common medi-
ating factor. In line with this hypothesis, we found a more frag-
mented sleep, as indicated by the higher hazard for sleep phase
transitions (wake to NREM, NREM to wake and REM to NREM) in
postmenopause compared to perimenopause, and for wake to
NREM transitions in relation to higher levels of melatonin. These
findings are partly consistent with those of a large community
cohort study of over 5500 participants aged 40 years and older,
showing that the overall and phase-specific (wake to NREM and
NREM to wake) sleep phase transition rates predicted self-reported
restless and light sleep, even after controlling for objective mea-
sures of sleep architecture [36]. Given their reciprocal intercon-
nection, it is tempting to speculate that gonadal hormones (eg, the
FSH), and the rate of change on their levels during postmenopause,
may act as a key regulator, possibly affecting the direction of the
association betweenmelatonin and sleep. However, this hypothesis
remains to be tested.
Our findings of lowest melatonin levels during the NREM sleep
are in line with those reported by Luboshitzky et al., who studied
six healthy and 23 hypogonadal young men, and found the lowest
serum melatonin levels during SWS and the highest during REM59sleep, irrespective of the testosterone levels [21]. On the contrary,
when examining plasma melatonin levels in seven healthy men
(22e49 years of age), Birkeland reported the highest levels during
the wake stage and the lowest during REM sleep [19]. A study
focused on plasma melatonin levels in relation to headache, found
the lowest melatonin values during wake, intermediate levels in
connection with the NREM sleep, and a peak during the REM stage
in the 10 healthy male controls, but not in the 36 male patients
(aged 26e67 years) [22]. On the contrary, Claustrat et al. found no
associations between nocturnal melatonin levels and sleep stages
in six healthy young men [20]. However, the comparability with
such studies is extremely limited, since they all included only male
and generally young populations. This is of crucial importance,
since both sleep and melatonin differ across genders [37,38].
Additionally, gonadal hormones and reproductive phases are
known to impact on women's sleep [39]. Recently, Obayashi et al.
hypothesized that the changes in sex hormones typical of the
menopausal period may account for their finding of lower urinary
melatonin levels in old women than in old men (60 years of age),
irrespective of their exposure to light [40]. Nevertheless, the
reciprocal relationships between melatonin, sleep stages, repro-
ductive function and sex hormones in women needs to be further
studied.
Taken together, our findings point to a relationship between
melatonin and sleep stages, differently in perimenopausal and
postmenopausal women; in particular, the NREM sleep, and its
transition both from and to wake, seems to be the most sensitive
both to melatonin and to reproductive phase. On this regard, it is
important to notice that the two melatonin receptors, MT1 and
MT2, are differently expressed in different brain regions, and
mediate different effects of melatonin on sleep (a REM-sleep-
promoting effect via MT1, and a NREM-sleep-promoting effect via
MT2). It has been hypothesized that melatonin regulates the
expression of its own receptors, thus resulting in the NREM/REM
alternations typical of the sleep cycle [41]. The regulatory effect of
melatonin on sleepmay be blunted with age, which has been found
to be associated with a reduction of MT1 density in the brain [42].
4.1. Strengths and limitations
The main limitation of this study is a small sample size. How-
ever, other previous studies on melatonin levels across sleep stages
were conducted on similarly small or even smaller samples. In
addition, as the study was carried out on a generally healthy pop-
ulation, the results cannot be generalized to larger populations
with chronic diseases. Moreover, even though sleep disorders were
not excluded on the basis of the PSG results, self-reported sleep
disorders were one of our exclusion criteria. The melatonin sam-
pling took place throughout the year, thus possibly influencing the
results. However, during their visit in the sleep laboratory the
women spent their time inside the building, slept in a room
without windows and the night-time illumination levels were
strictly controlled. Also, the high inter-individual variability in
melatonin levels may have biased the results. Furthermore, the
comparability with previous studies may be limited by the use of
different tissue samples (plasma, urine, saliva) for measuring
melatonin levels.
Even though the 1-h melatonin sampling may not fully capture
sleep stage differences during the majority of the sleep episodes,
the repeated serum sampling technique used for the melatonin
assessment is the best technique to measure melatonin phase,
duration and amplitude, in particular when frequent samples are
taken [43]. Additional strengths of the study include the high-
frequency collection of serum samples under strictly controlled
sleep laboratory conditions, which ensured the good quality of the
E. Toffol, N. Kalleinen, S.-L. Himanen et al. Sleep Medicine 81 (2021) 52e61samples. Furthermore, the strict exclusion criteria allowed us to
eliminate several confounding factors.
5. Conclusions
The results of this study suggest that the relationship between
melatonin and sleep architecture is different between perimeno-
pausal and postmenopausal women. After menopause, higher
concentrations of melatonin are associated with worse sleep,
especially with worse SWS. Postmenopausal state seems to be
related to more sleep phase transitions, especially to and from the
NREM stage. Whether the different patterns of melatonin-to-sleep
relationship before and after menopause are related to aging of the
reproductive system, and whether they are causatively associated
to menopausal sleep complaints, remain to be elucidated.
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